Kodiak's Zenkuda, Tabirafusp-Ted Clear Primary Endpoints in Daybreak AMD Trial

Kodiak Sciences has reported that both Zenkuda and tabirafusp-ted met their primary endpoints in the pivotal Daybreak trial evaluating the therapies in wet age-related macular degeneration (wAMD).

The company said Zenkuda demonstrated a profile that could represent a potential new standard of care, citing strong immediacy and a sustained clinical effect. A majority of patients in the study were maintained on a 24-week dosing interval under strict treat-to-dryness real-world retreatment criteria.

According to the company, both Zenkuda and tabirafusp-ted showed a safety profile consistent with that already established for aflibercept.

Kodiak Sciences said the Zenkuda biologics license application (BLA) is planned for the fourth quarter of 2026 and is set to include data from five positive Phase 3 studies.

The Daybreak results cover two of the company's investigational assets in a retinal disease that remains a major cause of vision loss, with treatment frequency a key consideration in clinical practice.